List of 10 in Vivo Gene Therapy Companies in the US

Free List Of Top 10 In Vivo Gene Therapy Companies

Innovative advancements in gene therapy have revolutionized the medical landscape, paving the way for potential treatments and cures for previously incurable diseases. In vivo gene therapy, in particular, involves the introduction of genetic material into a patient’s body to treat or prevent diseases. As the field continues to expand, several companies in the United States have emerged at the forefront of in vivo gene therapy, pioneering groundbreaking research and development. Here we present an overview of the top 10 in vivo gene therapy companies in the US, highlighting their sector, year founded, annual revenue, and a brief description of their contributions to the field.

Sector: Gene Therapy Advancements in the US

1. Regenxbio (SDAQ: RGNX)

– Year Founded: 2008

– Annual Revenue: $147.2 million (as of 2020)

– Description: Regenxbio focuses on the development, commercialization, and licensing of advanced gene therapy treatments. They have a diverse pipeline of product candidates aimed at addressing a range of genetic conditions.

– [Regenxbio Website](

2. Sangamo Therapeutics (SDAQ: SGMO)

– Year Founded: 1995

– Annual Revenue: $84.2 million (as of 2020)

– Description: Sangamo Therapeutics specializes in developing genomic therapies for a variety of diseases, with a focus on research and clinical trials for conditions such as hemophilia and genetic metabolic disorders.

– [Sangamo Therapeutics Website](

3. Audentes Therapeutics (Acquired by Astellas Pharma)

– Year Founded: 2012

– Annual Revenue: N/A

– Description: Audentes Therapeutics, now part of Astellas Pharma, is dedicated to the development of innovative gene therapy products for serious and rare diseases, particularly neuromuscular and central nervous system disorders.

– [Astellas Pharma Website](

4. Abeona Therapeutics (SDAQ: ABEO)

– Year Founded: 2012

– Annual Revenue: $4.79 million (as of 2020)

– Description: Abeona Therapeutics focuses on developing and delivering gene therapy and plasma-based therapeutics for various rare diseases, including both inherited genetic disorders and severe acquired diseases.

– [Abeona Therapeutics Website](

5. Orchard Therapeutics (SDAQ: ORTX)

– Year Founded: 2015

– Annual Revenue: $176.99 million (as of 2020)

– Description: Orchard Therapeutics is dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, with a focus on primary immune deficiencies and neurometabolic disorders.

– [Orchard Therapeutics Website](

6. Voyager Therapeutics (SDAQ: VYGR)

– Year Founded: 2013

– Annual Revenue: $51.4 million (as of 2020)

– Description: Voyager Therapeutics specializes in the development of gene therapy treatments for severe neurological diseases, including Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and Huntington’s disease.

– [Voyager Therapeutics Website](

7. Homology Medicines (SDAQ: FIXX)

– Year Founded: 2015

– Annual Revenue: $2.44 million (as of 2020)

– Description: Homology Medicines is dedicated to translating genetic breakthroughs into transformative therapies for patients with genetic disorders, focusing on genetic medicines for rare diseases and genetic cancers.

– [Homology Medicines Website](

8. LogicBio Therapeutics (SDAQ: LOGC)

– Year Founded: 2014

– Annual Revenue: $1.67 million (as of 2020)

– Description: LogicBio Therapeutics is committed to developing gene editing therapies for the treatment of rare diseases, using their GeneRide™ platform to deliver targeted, durable, and precise genetic therapies.

– [LogicBio Therapeutics Website](

9. Asklepios BioPharmaceutical (AskBio)

– Year Founded: 2001

– Annual Revenue: N/A

– Description: AskBio is a clinical-stage adeno-associated virus (AAV) gene therapy company focused on developing life-saving medicines for patients suffering from rare and genetically defined diseases.

– [AskBio Website](

10. Adverum Biotechnologies (SDAQ: ADVM)

– Year Founded: 2006

– Annual Revenue: $25.8 million (as of 2020)

– Description: Adverum Biotechnologies is dedicated to developing gene therapies for patients with sight-threatening diseases, including a pipeline of novel gene therapy candidates for retinal disorders.

– [Adverum Biotechnologies Website](

To summarize

The innovative approaches and promising advancements within the in vivo gene therapy sector continue to open doors to potentially transformative treatments for a multitude of diseases. The top 10 in vivo gene therapy companies in the US are leading the charge in research, development, and commercialization, with a collective commitment to improving patient outcomes and addressing previously unmet medical needs.